<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Ketorolac</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00465</strong>&#160; (APRD01060)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>A pyrrolizine carboxylic acid derivative structurally related to indomethacin. It is an <span class="caps">NSAID</span> and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed)</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00465/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00465/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00465.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00465.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00465.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00465.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00465.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00465">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Ketorolac</td><td>German</td><td>INN</td></tr><tr><td>K&#233;torolac</td><td>French</td><td>INN</td></tr><tr><td>Ketorolaco</td><td>Spanish</td><td>INN</td></tr><tr><td>Ketorolacum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Ketorolac Tromethamine</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT001045/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT001045/thumb.png"></a></td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT001045">DBSALT001045</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Acular</td><td>Allergan</td></tr><tr><td>ACUVAIL</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Bedoral</td><td>Be-Tabs Pharmaceuticals</td></tr><tr><td>Dolten</td><td>Pfizer</td></tr><tr><td>Dolten SL</td><td>Pfizer</td></tr><tr><td>Dorixina forte NF</td><td>Roemmers</td></tr><tr><td>Emodol</td><td>Jayson</td></tr><tr><td>Etorac</td><td>Incepta</td></tr><tr><td>Ketonic</td><td>Eskayef</td></tr><tr><td>Ketora</td><td>Medicon</td></tr><tr><td>Lixidol</td><td>Roche</td></tr><tr><td>Sprix</td><td>Luitpold</td></tr><tr><td>Syndol</td><td>Roche</td></tr><tr><td>Taradyl</td><td>Roche</td></tr><tr><td>Tarasyn</td><td>Roche</td></tr><tr><td>Toradol</td><td>Roche</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Gammadol</td><td>Ketorolac and Tramadol</td></tr><tr><td>Libramest</td><td>Ketorolac and Homatropine</td></tr><tr><td>Maxidol Compuesto</td><td>Ketorolac and Homatropine</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/anti-inflammatory-agents-non-steroidal">Anti-Inflammatory Agents, Non-Steroidal</a></li>
<li><a href="/mesh/cyclooxygenase-inhibitors">Cyclooxygenase Inhibitors</a></li></ul></td></tr><tr><th>CAS number</th><td>66635-83-4</td></tr><tr><th>Weight</th><td>Average: 255.2686<br>Monoisotopic: 255.089543287</td></tr><tr><th>Chemical Formula</th><td>C<sub>15</sub>H<sub>13</sub>NO<sub>3</sub></td></tr><tr><th>InChI Key</th><td>OZWKMVRBQXNZKK-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C15H13NO3/c17-14(10-4-2-1-3-5-10)13-7-6-12-11(15(18)19)8-9-16(12)13/h1-7,11H,8-9H2,(H,18,19)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid</div></td></tr><tr><th>SMILES</th><td><div class="wrap">OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Acetophenones</td></tr><tr><th>Direct parent</th><td>Acetophenones</td></tr><tr><th>Alternative parents</th><td>Benzoyl Derivatives; Pyrrolizines; Substituted Pyrroles; Ketones; Enolates; Carboxylic Acids; Polyamines</td></tr><tr><th>Substituents</th><td>benzoyl; pyrrolizine; substituted pyrrole; pyrrole; ketone; polyamine; enolate; carboxylic acid; carboxylic acid derivative; carbonyl group; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the acetophenones. These are organic compounds containing the acetophenone structure.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the short-term (~5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting.</td></tr><tr><th>Pharmacodynamics</th><td>Ketorolac, an antiinflammatory agent with analgesic and antipyretic properties, is used to treat osteoarthritis and control acute pain. It is a peripherally acting analgesic. The biological activity of ketorolac tromethamine is associated with the S-form. Ketorolac tromethamine possesses no sedative or anxiolytic properties.</td></tr><tr><th>Mechanism of action</th><td>Ketorolac is a nonsteroidal anti-inflammatory drug (NSAID) chemically related to indomethacin and tolmetin. Ketorolac tromethamine is a racemic mixture of [-]S- and [+]R-enantiomeric forms, with the S-form having analgesic activity. Its antiinflammatory effects are believed to be due to inhibition of both cylooxygenase-1 (COX-1) and cylooxygenase-2 (COX-2) which leads to the inhibition of prostaglandin synthesis leading to decreased formation of precursors of prostaglandins and thromboxanes from arachidonic acid. The resultant reduction in prostaglandin synthesis and activity may be at least partially responsible for many of the adverse, as well as the therapeutic, effects of these medications. Analgesia is probably produced via a peripheral action in which blockade of pain impulse generation results from decreased prostaglandin activity. However, inhibition of the synthesis or actions of other substances that sensitize pain receptors to mechanical or chemical stimulation may also contribute to the analgesic effect. In terms of the ophthalmic applications of ketorolac - ocular administration of ketorolac reduces prostaglandin E2 levels in aqueous humor, secondary to inhibition of prostaglandin biosynthesis.</td></tr><tr><th>Absorption</th><td>Rapidly and completely absorbed after oral administration</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>0.26 &#177; 0.08 L/kg [children 4 to 8 years old]</li>
</ul></td></tr><tr><th>Protein binding</th><td>99%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Primarily hepatic. Less than 50% of a dose is metabolized. The major metabolites are a glucuronide conjugate, which may also be formed in the kidney, and p-hydroxy ketorolac. Neither metabolite has significant analgesic activity.</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Ketorolac</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00978">4-hydroxy ketorolac</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1000">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>The principal route of elimination of ketorolac and its metabolites is renal. Approximately 6% of a dose is excreted in the feces.</td></tr><tr><th>Half life</th><td>2.5 hours for the S-enantiomer compared with 5 hours for the R-enantiomer</td></tr><tr><th>Clearance</th><td><ul>
	<li>0.042 +/- 0.01 L/hr/kg [Pediatric Patients]</li>
	<li>0.02 L/h/kg [Normal Subjects IM]</li>
	<li>0.03 L/h/kg [Normal Subjects oral]</li>
	<li>0.02 L/h/kg [Healthy Elderly Subjects IM]</li>
	<li>0.02 L/h/kg [Healthy Elderly Subjects oral]</li>
	<li>0.03 L/h/kg [Patients with Hepatic Dysfunction IM]</li>
	<li>0.03 L/h/kg [Patients with Hepatic Dysfunction oral]</li>
	<li>0.02 L/h/kg [Patients with Renal Impairment IM]</li>
	<li>0.02 L/h/kg [Patients with Renal Impairment oral]</li>
	<li>0.02 L/h/kg [Renal Dialysis Patients IM]</li>
</ul></td></tr><tr><th>Toxicity</th><td>LD<sub>50</sub> = 189 mg/kg (rat, oral).</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th></tr></thead><tbody><tr><td>Ketorolac Action Pathway</td><td>Drug action</td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9919</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.7918</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.8957</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.7127</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9624</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8684</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.6042</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7845</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.7046</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.6338</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.5483</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9081</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9333</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9225</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9621</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9467</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.7615
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9592
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.5254
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.5902 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9478
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.9298
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Akorn strides llc</li>
<li>Amphastar pharmaceutical inc</li>
<li>Apotex inc richmond hill</li>
<li>Apothecon inc div bristol myers squibb</li>
<li>App pharmaceuticals llc</li>
<li>Baxter healthcare corp anesthesia and critical care</li>
<li>Baxter healthcare corp anesthesia critical care</li>
<li>Bedford laboratories div ben venue laboratories inc</li>
<li>Claris lifesciences ltd</li>
<li>Gland pharma ltd</li>
<li>Hospira inc</li>
<li>Luitpold pharmaceuticals inc</li>
<li>Sandoz canada inc</li>
<li>Sun pharma global inc</li>
<li>Wockhardt ltd</li>
<li>Roche palo alto llc</li>
<li>Allergan inc</li>
<li>Allergan</li>
<li>Akorn inc</li>
<li>Alcon inc</li>
<li>Roxro pharma inc</li>
<li>Mylan pharmaceuticals inc</li>
<li>Pliva inc</li>
<li>Roxane laboratories inc</li>
<li>Teva pharmaceuticals usa inc</li>
<li>Watson laboratories inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.akorn.com">Akorn Inc.</a></li>
<li><a href="http://www.allergan.com">Allergan Inc.</a></li>
<li><a href="http://www.amerisourcebergen.com">Amerisource Health Services Corp.</a></li>
<li><a href="http://www.apotex.com">Apotex Inc.</a></li>
<li>Apotheca Inc.</li>
<li>Apothecary Shop Wholesale</li>
<li><a href="http://www.apppharma.com">APP Pharmaceuticals</a></li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://www.baxter.com">Baxter International Inc.</a></li>
<li><a href="http://www.bedfordlabs.com">Bedford Labs</a></li>
<li><a href="http://www.benvenue.com">Ben Venue Laboratories Inc.</a></li>
<li><a href="http://bryantranchprepack.com">Bryant Ranch Prepack</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li><a href="http://www.corepharma.com">Corepharma LLC</a></li>
<li><a href="http://www.curapharma.com">Cura Pharmaceutical Co. Inc.</a></li>
<li>Direct Dispensing Inc.</li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li><a href="http://www.ethex.com">Ethex Corp.</a></li>
<li><a href="http://www.roche.com">F Hoffmann-La Roche Ltd.</a></li>
<li><a href="http://www.falconpharma.com">Falcon Pharmaceuticals Ltd.</a></li>
<li><a href="http://www.giv.com">General Injectables and Vaccines Inc.</a></li>
<li><a href="http://hjharkinscompanyinc.com">H.J. Harkins Co. Inc.</a></li>
<li><a href="http://www.hospira.com">Hospira Inc.</a></li>
<li><a href="http://www.innoviantpharmacy.com">Innoviant Pharmacy Inc.</a></li>
<li>Kaiser Foundation Hospital</li>
<li><a href="http://www.keltman.com">Keltman Pharmaceuticals Inc.</a></li>
<li>Lake Erie Medical and Surgical Supply</li>
<li><a href="http://www.mckesson.com">Mckesson Corp.</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li>Neuman Distributors Inc.</li>
<li>Novex Pharma</li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.palmettopharm.com">Palmetto Pharmaceuticals Inc.</a></li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.pliva.com">Pliva Inc.</a></li>
<li><a href="http://www.preferredpharmaceuticals.com">Preferred Pharmaceuticals Inc.</a></li>
<li><a href="http://www.prescript.net">Prescript Pharmaceuticals</a></li>
<li><a href="http://www.rebelrx.com">Rebel Distributors Corp.</a></li>
<li>Redpharm Drug</li>
<li>Resource Optimization and Innovation LLC</li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li><a href="http://www.spectrumpharm.com">Spectrum Pharmaceuticals</a></li>
<li>St Mary's Medical Park Pharmacy</li>
<li><a href="http://statrxusa.exporterus.com">Stat Rx Usa</a></li>
<li><a href="http://www.stridesarco.com">Strides Arcolab Limited</a></li>
<li><a href="http://www.sunpharma.com">Sun Pharmaceutical Industries Ltd.</a></li>
<li><a href="http://www.syntexar.com">Syntex SA</a></li>
<li>Taylor Pharmaceuticals</li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li><a href="http://www.wockhardtin.com">Wockhardt Ltd.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Liquid</td><td>Intramuscular</td><td></td></tr><tr><td>Solution</td><td>Intramuscular</td><td></td></tr><tr><td>Solution</td><td>Ophthalmic</td><td></td></tr><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01418">Acenocoumarol</a></td><td>The NSAID, ketorolac, may increase the anticoagulant effect of acenocoumarol.</td></tr><tr><td><a href="/drugs/DB00945">Acetylsalicylic acid</a></td><td>Acetylsalicylic acid may increase the adverse GI effects ketorolac.</td></tr><tr><td><a href="/drugs/DB00630">Alendronate</a></td><td>Increased risk of gasrtic toxicity</td></tr><tr><td><a href="/drugs/DB01125">Anisindione</a></td><td>The NSAID, ketorolac, may increase the anticoagulant effect of anisindione.</td></tr><tr><td><a href="/drugs/DB08822">Azilsartan medoxomil</a></td><td>Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. </td></tr><tr><td><a href="/drugs/DB00930">Colesevelam</a></td><td>Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam. </td></tr><tr><td><a href="/drugs/DB00266">Dicoumarol</a></td><td>The NSAID, ketorolac, may increase the anticoagulant effect of dicumarol.</td></tr><tr><td><a href="/drugs/DB06781">Difluprednate</a></td><td>NSAIDs may slow healing. </td></tr><tr><td><a href="/drugs/DB06210">Eltrombopag</a></td><td>Increases levels of Ketorolac via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance. </td></tr><tr><td><a href="/drugs/DB01381">Ginkgo biloba</a></td><td>Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB01009">Ketoprofen</a></td><td>Concomitant use of ketoprofen and ketorolac, two NSAIDs, is contraindicated due to the risk of additive or synergistic NSAID toxicities (e.g. GI bleeding, ulceration, renal dysfunction, etc).  </td></tr><tr><td><a href="/drugs/DB01356">Lithium</a></td><td>The NSAID, ketorolac, may decrease the renal excretion of lithium. Increased risk of lithium toxicity.</td></tr><tr><td><a href="/drugs/DB00563">Methotrexate</a></td><td>The NSAID, ketorolac, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.</td></tr><tr><td><a href="/drugs/DB01032">Probenecid</a></td><td>Probenecid increases toxicity of ketorolac</td></tr><tr><td><a href="/drugs/DB00605">Sulindac</a></td><td>May cause additive or synergistic NSAID toxicities (e.g. GI bleeding, renal dysfunction, etc.). Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB00966">Telmisartan</a></td><td>Concomitant use of Telmisartan and Ketorolac may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment. </td></tr><tr><td><a href="/drugs/DB01600">Tiaprofenic acid</a></td><td>Concomitant therapy is contraindicated due to the risk of synergistic NSAID toxicity.</td></tr><tr><td><a href="/drugs/DB00373">Timolol</a></td><td>The NSAID, Ketorolac, may antagonize the antihypertensive effect of Timolol.</td></tr><tr><td><a href="/drugs/DB00500">Tolmetin</a></td><td>Risk of adverse NSAID toxic effects (e.g. GI bleeding, renal dysfunction). Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00519">Trandolapril</a></td><td>The NSAID, Ketorolac, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Ketorolac is initiated, discontinued or dose changed.  </td></tr><tr><td><a href="/drugs/DB00374">Treprostinil</a></td><td>The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Ketorolac. Monitor for increased bleeding during concomitant thearpy. </td></tr><tr><td><a href="/drugs/DB06684">Vilazodone</a></td><td>Increased risk of bleeding with concomitant use of vilazodone and ketorolac</td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>The antiplatelet effects of ketorolac may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Take with food to reduce GI irritation</li></ul></td></tr></tbody></table>